Transaction #7740 · Form 4 · 0001104659-25-111627
PHIBRO ANIMAL HEALTH CORP · Conversion · Class A Common Stock
PHIBRO ANIMAL HEALTH CORP · Transacted November 11, 2025 · Filed November 13, 2025
What does this filing report?
An SEC Form 4 filing for PHIBRO ANIMAL HEALTH CORP records a conversion involving Class A Common Stock on November 11, 2025. The reported quantity was 15,000. The filing date is November 13, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- PHIBRO ANIMAL HEALTH CORP
- Company CIK
- 0001069899
- Security type
- Non-derivative
- Acquisition type
- Conversion · Code C
- Quantity acquired
- 15,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 35,577
- Ownership description
- See
- SEC acceptance time
- Nov 13, 2025, 8:24 PM EST
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- BENDHEIM JACK ↗
President and CEO · Director · 10% owner
CIK 0001241560
- BFI Co., LLC ↗
10% owner
CIK 0001601607
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Filing footnotes & remarks
- F1
- Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.
- F2
- The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- F3
- The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.
- F4
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.95 to $45.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 5 and 6.
- F5
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.84 to $44.78.
- F6
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.86 to $45.465.
- F7
- The reported securities are directly held by Jack Bendheim.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.